Print
|
Close
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Active:
No
Cancer Type:
Multiple Myeloma
NCT ID:
NCT04722146
Trial Phases:
Phase I
Protocol IDs:
CR108927 (primary)
NCI-2021-02225
64007957MMY1004
2020-004404-33
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
Janssen Research & Development, LLC
NCI Full Details:
http://clinicaltrials.gov/show/NCT04722146
Summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when
administered in different combination regimen and to identify the optimal dose(s) of
teclistamab combination regimens.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.